Navigation Links
Clinical Trial Establishes Catheter-Based Aortic Valve Replacement as New Standard of Care for Patients Who Cannot Undergo Surgery
Date:9/22/2010

WASHINGTON, Sept. 22 /PRNewswire/ -- One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis. The results will be presented tomorrow as a Late Breaking Trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Transcatheter aortic-valve implantation (TAVI) is a new procedure in which a bioprosthetic valve is inserted through a catheter and implanted within the diseased native aortic valve. The Placement of AoRtic TraNscathetER valves (PARTNER) trial is a multicenter, randomized clinical trial comparing TAVI with standard therapy in high-risk patients with severe aortic stenosis. The co-principal investigators are Martin B. Leon, M.D., and Craig R. Smith, M.D., at NewYork-Presbyterian Hospital/Columbia University Medical Center. The data published today reflect a prespecified cohort of patients who were considered to be unsuitable candidates for surgery.

The primary end point was the rate of death from any cause over the duration of the study. A total of 358 patients with aortic stenosis who were considered to be unsuitable candidates for surgery underwent randomization at 21 centers, including 17 in the United States. Patients randomized for standard therapy received a combination of watchful waiting, medications, and balloon aortic valvuloplasty, which can provide transient clinical benefit but does not alter long-term outcomes.

At one year, patients who underwent TAVI showed a 45 percent reduction in the rate of death from any cause compared with patients who received standard therapy (30.7 percent vs. 50.7 percent) and a 54 percent reduction in the combined end point of death from any cause or repeat hospitalization (42.5 percent with TAVI vs. 71.6 percent with
'/>"/>

SOURCE NewYork-Presbyterian Hospital/Columbia University Medical Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... SPRINGDALE, Ark. , Sept. 1, 2015 NOWDiagnostics Inc., ... completed its acquisition of ZBx Corporation of Canada ... to its vision of a world where people have ... NOWDiagnostics manufactures and sells a line of unique blood-based ... simple-to-use, highly accurate tests for a variety of ailments ...
(Date:9/1/2015)... 1, 2015 UT Southwestern Medical Center President ... members joined U.S. Representatives Michael C. Burgess , ... discussion on the 21 st Century Cures Act, ... considered by the United States ... Academy of Sciences members, department chairs, center directors, and ...
(Date:9/1/2015)... Sept. 1, 2015  Results from an interim analysis ... that 5g of idarucizumab enabled emergency surgery to ... treated with dabigatran (Pradaxa ® dabigatran etexilate ... effect of dabigatran enabled patients to be urgently ... of 1.7 hours between administration of idarucizumab and ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9
... in wake of AHA-presented data , ... a clinical trial suggesting rosuvastatin may lower the cardiovascular risk ... statin use in older adults, according to a national poll ... the online poll conducted by medical news site MedPage Today ...
... FRANCISCO, Calif., Nov. 25 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... on,innovative oncology therapies, announced today that it will ... in order to allow,the Company to focus its ... product candidate, and to support the initial commercialization ...
Cached Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... survey to aid colleges and universities across the country in stemming sexual assaults ... Researcher Campus Climate Collaborative (ARC3), a consortium of sexual assault researchers and student ...
(Date:9/1/2015)... ... September 01, 2015 , ... Negative pressure wound therapy (NPWT) ... to remove exudates, fluid, and infectious materials to prepare the wound for healing ... devices, and canisters, etc.) is projected to expand continuously through 2021. , Rising ...
(Date:9/1/2015)... , ... September 01, 2015 , ... The Jerry Segal ... The ACE Club and Green Valley Country Club in Lafayette Hill, PA. Over the ... more than $13.5 million for programs and services designed to support patients and their ...
(Date:9/1/2015)... ... , ... Royal River Natural Foods, a locally-owned independent natural health store in ... years and found that, among those who had a stroke, people who used multivitamins ... of the September 2015 issue of “Natural Insights for Well Being,” which Royal River ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Agriculture innovation, urban ... few of the topics to be discussed at Seedstock’s 4th Annual Sustainable Agriculture ... at UC San Diego. , In addition to keynotes Pierre Sleiman, founder and ...
Breaking Medicine News(10 mins):Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 4Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 5
... Ill., Feb. 29 Landauer, Inc. (NYSE:,LDR) announced today ... dividend of $0.50 per share for the second quarter ... 4, 2008, to shareholders of record,on March 14, 2008., ... of analytical services to determine,occupational and environmental radiation exposure. ...
... Genoptix, Inc.,(Nasdaq: GXDX ), today announced the ... by certain existing stockholders to,the public at the price ... proceeds from the sale. The offer is expected to ... made through an underwriting syndicate led by,Lehman Brothers, Inc. ...
... Xing,Mobile Communication Co., Ltd. (,Qiao Xing Mobile, or ,the ... manufacturers of mobile,handsets through its subsidiary CEC Telecom Co., ... cardiograph mobile handset., The C7000A has the ... be able to perform a basic ...
... respiratory diseases like chronic bronchitis, but genes also play ... in Sweden, who studied more than 40,000 Swedish twins ... genes each play a role ion the development of ... known genetic component and smoking is a primary risk ...
... TULSA, Okla., Feb. 28 Presidential campaign fever is,running ... can,t hold a,candle to the presidential star power that ... Saturday night, March 1st, when they host the 16th,President ... Mr. Lincoln will be addressing Tulsa,s top doctors ...
... blood thinner continues , , THURSDAY, Feb. 28 (HealthDay News) ... center of recent problems with its blood thinner heparin, ... vials of the drug as well as single-dose vials. ... Hep-Lock heparin flush products, which contain a small amount ...
Cached Medicine News:Health News:Genoptix Announces Pricing of Secondary Public Offering 2Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 2Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 3Health News:Genetic factors in smoking also increase risk of chronic bronchitis 2Health News:Baxter Recalls Rest of Heparin Products 2Health News:Baxter Recalls Rest of Heparin Products 3
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
Medicine Products: